Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797779 | 0.87 | SMN1; SMN2 (0.46) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL7404251 | 0.84 | GAA (0.49) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL8135381 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL27862571 | 0.84 | TSHR (0.50) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL15398667 | 0.84 | SMN1; SMN2 (0.50) | ALDH1A1GAAMAPTHPGDTSHR | |
| SCHEMBL28404963 | 0.83 | GAA (0.46) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL2427891 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTALOX15TSHR | |
| SCHEMBL136404 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL18737796 | 0.81 | SMN1; SMN2 (0.42) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL543239 | 0.81 | SMN1; SMN2 (0.42) | ALDH1A1KDM4EGAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50594-E1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-09-23 | — | — | US | disclosed |
| CN-119569740-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569739-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569741-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-108026052-B | 5-hydroxyalkyl benzimidazoles as mIDH1 inhibitors | 德国癌症研究公共权益基金会 | 2021-10-08 | — | — | CN | disclosed |
| CN-113214270-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108137590-B | Spiro (3H-indol-3, 2' -pyrrolidin) -2(1H) -one compounds and their derivatives as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3359542-B1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | TP53, MDM2, FOXM1 | ALDH1A1 700/4885KDM4E 3169/4885GAA 3274/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | ALDH1A1 323/4885KDM4E 4402/4885GAA 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.